A novel herpesvirus amplicon system for in vivo gene delivery

Gene Therapy

Volumn 4, Issue 11, 1997, Pages 1132-1141

  Wang, S ^a   Di, S ^a   Young, W B ^a   Jacobson, C ^b   Link Jr , C J ^a  

^a Iowa Health System   (United States)

^b IOWA STATE UNIVERSITY   (United States)

Author keywords

Amplicon; Epstein Barr virus; Gene therapy; Herpes simplex virus; Viral vectors

Indexed keywords

VIRUS NUCLEOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; CELL LINE; CONTROLLED STUDY; EPISOME; EPSTEIN BARR VIRUS; EXPRESSION VECTOR; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; HELPER VIRUS; HERPES SIMPLEX VIRUS 1; HERPES VIRUS; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPORTER GENE; TRANSGENE; VIRION; VIRUS ASSEMBLY; VIRUS CAPSID; VIRUS RECOMBINANT; VIRUS REPLICATION;

ANIMALIA; HERPES; HERPESVIRIDAE; HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 4; MIRIDAE; SIMPLEXVIRUS;

EID: 0030733144     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300523     Document Type: Article

References (38)

1. Anderson WF. Human gene therapy. Science 1992; 226: 401-403.
2. Miller AD Retroviral vectors. Curr Top Microbiol Immunol 1992; 158: 1-24.
3. Mulligan RC. The basic science of human gene therapy. Science 1993; 260: 926-932.
4. Crystal RG. Transfer of genes to humans: early lessons and obstacles to success. Science 1995; 270: 404-410.
5. Wilson JM. Adenoviruses as gene delivery vehicles. New Engl J Med 1996; 334: 1185-1187.
6. Naldini L et al. In vivo gene delivery and stable transduction of nondividing cells by a Lentiviral vector. Science 1996; 272: 263-267.
7. Hill TJ. Herpes simplex virus latency. In: Roizman B (ed). The Herpesviruses. Plenum Press: New York, 1985, pp 175-240.
8. Glorioso JC, DeLuca NA, Fink DJ. Development and application of herpes simplex virus vectors for human gene therapy. Annu Rev Microbiol 1995; 49: 675-710.
9. Fields B, Knipe D, Howley P. Fields Virology: Herpes Simplex Viruses and Their Replication. Lippincott-Raven: Philadelphia, 1996, pp 2231-2296.
10. Honess RW, Roizman B. Regulation of herpes virus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins. J Virol 1974; 14: 8-19.
11. DeLuca NA, Schaffer PA. Activation of immediate-early, early, and late promoters by temperature sensitive and wild-type forms of herpes simplex virus type 1 protein ICP4. Mol Cell Biol 1985; 5: 1997-2009.
12. DeLuca NA, McCarthy AM, Schaffer PA. Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4. J Virol 1985; 56: 558-570.
13. DeLuca NA, Schaffer PA. Activities of herpes simplex virus type 1 (HSV-1) ICP4 genes specifying nonsense peptides. Nucleic Acids Res 1987; 15: 4491-4511.
14. Johnson PA et al. Cytotoxicity of a replication-defective mutant of herpes simplex virus type 1. J Virol 1992; 66: 2952-2965
15. Sabel BA, Vick A, Holt V. Neurotoxic reactions of CNS following gene transfer with defective herpes simplex virus (HSV-1) vector. NeuroReport 1995; 6: 2447-2449.
16. Spaete RR, Frenkel N. The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector. Cell 1982; 30: 295-304.
17. Kwong AD, Frenkel N. Herpes simplex virus amplicon: effect of size on replication of constructed defective genomes containing eukaryotic DNA sequences. J Virol 1984; 51: 595-603.
18. Geller AI, Breakefield XO. A defective HSV-1 vector expresses Escherichia coli β-galactosidase in cultured peripheral neurons. Science 1988; 241: 1667-1669.
19. Geller AI, Freese A. Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of Escherichia coli β-galactosidase. Proc Natl Acad Sci USA 1990; 87: 1149-1153.
20. Palella TD et al. Expression of human HPRT mRNA in brains of mice infected with a recombinant herpes simplex type 1 vector. Gene 1989; 80: 137-144.
21. Chiocca EA et al. Transfer and expression of the lacZ gene in rat brain neurons by herpes simplex virus mutants. New Biol 1990; 2: 739-746.
22. Anderson JK et al. Gene transfer into mammalian central nervous system using herpesvirus vectors: extended expression of bacterial lacZ gene in neurons using the neuron-specific enolase promoter. Hum Gene Ther 1992; 3: 487-499.
23. Ho D, Mocarski E, Sapoloski R. Altering central nervous system physiology with a defective herpes simplex virus vector expressing the glucose transporter gene. Proc Natl Acad Sci USA 1993; 90: 3655-3659.
24. During MJ et al. Long-term behavioral recovery in Parkinsonian rats by an HSV vector expressing tyrosine hydroxylase. Science 1994; 266: 1399-1403.
25. Wang S, Vos J. A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. J Virol 1996; 70: 8422-8430.
26. Yates JL, Warren N, Sugden B. Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 1985; 313: 812-815.
27. Reisman D, Yates J, Sugden B. A putative origin of replication of plasmids derived from Epstein-Barr virus is composed of two cis-acting components. Mol Cell Biol 1985; 5: 1822-1832.
28. Rawlins DR et al. Sequence-specific interactions of cellular nuclear factor I and Epstein-Barr virus nuclear antigen with herpes virus DNAs. Cancer Cell 1986; 4: 525-542.
29. Goldsmith K, Bendell L, Frappier L. Identification of EBNA1 amino acid sequences required for the interaction of the functional elements of the Epstein-Barr virus latent origin of DNA replication. J Virol 1993; 67: 3418-3426.
30. Judde JG et al. Use of Epstein-Barr virus nuclear antigen-1 in targeted therapy of EBV-associated neoplasia. Hum Gene Ther 1996; 7: 647-653.
31. Muldoon RR et al. Tracking and quantitation of retroviral mediated transfer using a humanized, red shifted green fluorescent protein gene. BioTechniques 1997; 22: 162-167.
32. Section 1: Escherichia coli, plasmids, and baeteriophages. In: Ausubel FM (ed). Current Protocols in Molecular Biology. John Wiley and Sons: New York, 1989, pp 1.4.2-1.4.3.
33. Fraefel C et al. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 1996; 70: 7190-7197.
34. Kochanek S et al. A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently coexpressing both full-length dystrophin and β-galactosidase. Proc. Natl Acad Sci USA 1996; 93: 5731-5736.
35. Starr P et al. Long-term persistence of defective HSV-1 vectors in the rat brain is demonstrated by reactivation of vector gene expression. Gene Therapy 1996; 3: 615-623.
36. Martuza RL et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991; 252: 854-856.
37. Boviatsis EJ et al. Long-term survival of rats harboring brain neoplasms treated with ganciclovir and a herpes simplex virus vector that retains an intact thymidine kinase gene. Cancer Res 1994; 54: 5745-5751.
38. Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol 1967; 26: 365-369.